amodiaquine hydrochloride / Generic mfg. - LARVOL DELTA

Amodiaquine Modulates Aggregation and Disassembly of Amyloid-β and Tau and Attenuates Neuroinflammatory Responses and Aβ Production. (PubMed, Pharmaceutics) - "In APP-H4 cells, 10 μM AQ decreased the level of Aβ compared to the control. AQ modulates both Aβ and tau aggregation and attenuates neuroinflammation and reduces Aβ pathology, supporting its potential as a dual-target therapeutic candidate for AD."

Journal • Alzheimer's Disease • CNS Disorders • Infectious Disease • Inflammation • IL6 • TNFA

Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (clinicaltrials.gov) - P4 | N=1000 | Active, not recruiting | Sponsor: Liverpool School of Tropical Medicine | Recruiting ➔ Active, not recruiting

Enrollment closed • Anemia • Hematological Disorders • Infectious Disease • Malaria

FD-TACT: A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines (clinicaltrials.gov) - P3 | N=1680 | Recruiting | Sponsor: University of Oxford | Not yet recruiting ➔ Recruiting | Trial completion date: May 2025 ➔ Jul 2026 | Trial primary completion date: Nov 2024 ➔ Jul 2026

Enrollment open • Head-to-Head • Trial completion date • Trial primary completion date • Infectious Disease • Malaria

DeTACT-Africa: A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs. (clinicaltrials.gov) - P3 | N=2583 | Completed | Sponsor: University of Oxford | Recruiting ➔ Completed

Head-to-Head • Trial completion • Infectious Disease • Malaria

WITHDRAWN Understanding cohort retention: findings from a seasonal malaria chemoprevention efficacy study in Niassa, Mozambique (ASTMH 2025) - "This analysis utilised data from a CPES in which a cohort of children were prospectively recruited in four communities, underwent a baseline assessment, received a three-day course of sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) and were followed up for up to 28 days to monitor incidence of malaria infection. There was substantial attrition in the study. Dropout rates varied across study communities, suggesting the influence of individual and contextual factors."

Clinical • Infectious Disease • Malaria

WITHDRAWN Assessing spatial and temporal trends in seasonal malaria chemoprevention coverage and other key indicators, and identifying factors associated with the trends in Nampula Province, Mozambique. (ASTMH 2025) - "In 2020, a mid-term review of Mozambique's Malaria Strategic Plan recommended the adoption of seasonal malaria chemoprevention (SMC) using sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) to accelerate malaria control. Conversely, children whose caregivers had limited SMC knowledge had lower odds of receiving Day 1 SPAQ compared with those of more knowledgeable caregivers (Odds ratio, 0.68 [95% CI: 0.47- 0.98]). Future interventions should focus on strengthening caregiver engagement and refining distribution strategies, especially in underperforming districts."

Infectious Disease • Malaria

Pharmacometric evaluation of sulfadoxine-pyrimethamine- amodiaquine and dihydroartemisinin-piperaquine seasonal malaria chemoprevention in northern Uganda. (PubMed, Clin Infect Dis) - "SPAQ SMC had low clinical and parasitological chemopreventive efficacy in Northern Uganda whereas dihydroartemisinin-piperaquine was effective."

Journal • Infectious Disease • Malaria

Is Seasonal Malaria Chemoprevention with Sulfadoxine-Pyrimethamine/Amodiaquine Appropriate in East Africa? (PubMed, Clin Infect Dis) - No abstract available

Journal • Infectious Disease • Malaria

Parasitological efficacy of seasonal malaria chemoprevention in Nampula, northern Mozambique. (PubMed, Trans R Soc Trop Med Hyg) - "In Nampula, northern Mozambique, amodiaquine had low parasitological efficacy and sulphadoxine and pyrimethamine did not contribute significantly to chemoprevention."

Journal • Infectious Disease • Malaria

Quinine-Hemin Compound As an Anti-Inflammatory Therapy in Sickle Cell Disease (ASH 2024) - "In addition to quinine, we tested the effect of combination hemin with chloroquine, amodiaquine, and dihydroartemisinin on IL-1β, and no effect was identified at the concentration of 2.5 µM. Our data support that QHC inhibits inflammasome activation both in vitro and in vivo. In summary, our data support the use of hemin-binding small molecules as potential therapeutics for SCD and other inflammasome activated diseases."

Genetic Disorders • Hematological Disorders • Infectious Disease • Inflammation • Malaria • Sickle Cell Disease • HPX • IFNB1 • IL1B • IL6 • NLRP3 • TNFA

Global medium-term research priority setting for seasonal malaria chemoprevention: results from an eDelphi study. (PubMed, BMJ Glob Health) - "Research priorities related to sustainability, antimalarial resistance, integration with other interventions and improving quality of SMC delivery featured prominently among the highest-ranked research priorities. It is hoped the results of this consultation can encourage research uptake, guide new research and inform programme adaptation."

Journal • Infectious Disease • Malaria

Low pfcrt-76T and High pfdhfr-dhps Quadruple Mutant Genotype Prevalence after 10 Years of Seasonal Malaria Chemoprevention Implementation in Mali (AMP 2025) - "In 2014, SMC increased the prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxinepyrimethamine (SP) in the treated children but not in the non-SMC population...Children aged 3 to 59 months received several rounds of SP plus amodiaquine (SP+AQ) over 10 malaria seasons... SMC increased the prevalence of quadruple mutant of P. falciparum resistance to SP in the treated children and non-SMC population 10 years after SMC scale-up in Mali. In contrast, a low prevalence of pfcrt-76T was observed after several years of SMC implementation in Mali."

Infectious Disease • Malaria • ABCB1 • DHFR

Peripheral immune cell-specific genes in Parkinson's disease uncovered by multi-omics with therapeutic implications. (PubMed, NPJ Parkinsons Dis) - "Drug repurposing analysis identified several candidate compounds, including felodipine, amodiaquine, alprazolam, and tetrandrine, some of which are predicted to cross the blood-brain barrier. Molecular docking simulations further supported strong binding interactions between these compounds and PD-associated targets such as CTSB and ARSA. This integrative approach highlights key immune-cell-specific genes involved in PD and proposes several repurposable drugs with central nervous system potential, paving the way for more targeted therapeutic strategies."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • CD4 • CD8 • FDFT1 • HLA-DQA1

Logistics Preparedness: Ensuring Timely Commodity Availability for Large-Scale ITN and SMC Integrated Malaria Campaigns (ASTMH 2025) - "Strategic logistics planning and execution were implemented to support the large-scale delivery of ITNs and Sulfadoxine Pyrimethamine and Amodiaquine (SPAQ) for SMC to each of the states ahead of the integrated campaigns. These strategies ensured commodity availability in integrated malaria campaigns that could be replicated in future integrated health interventions. Strengthening logistics preparedness for integrated malaria campaigns in Nigeria remains a cornerstone of achieving universal health coverage while ensuring commodity availability for malaria elimination."

Infectious Disease • Malaria

Impact of seasonal malaria chemoprevention on antimalarial drug resistance and the emergence of non-falciparum species in Karamoja sub-region, Uganda (ASTMH 2025) - "No parasite isolate carried markers associated with high level resistance to sulphadoxine pyrimethamine (SP) or amodiaquine (AQ). Our data suggests a potential emergence of non-falciparum species following SMC which is likely to increase with repeated rounds. SPAQ remains effective for SMC but there is need for continued monitoring for antifolate, transporter and K13 mutations in SMC-implementing areas and neighboring communities."

Infectious Disease • Malaria

Effectiveness of using seasonal malaria chemoprevention (SMC) as a platform for integrated codelivery of albendazole and praziquantel in West African children: a cluster randomised, controlled trial (ASTMH 2025) - "Both clusters subsequently received SMC with sulfadoxine-pyrimethamine on Day 1 and amodiaquine on Days 1-3. Integrated codelivery of preventive chemotherapy/mass drug administration (MDA) for helminths with SMC drugs was safe, tolerated and effective in reducing anaemia associated with malaria-helminth co-infections among Ghanaian school-aged children. This is the first study reporting effectiveness of integrated SMC-MDA among school-aged children and the findings could inform adoption of an integrated SMC-MDA campaign for improved effectiveness and impact among children living in the poorest countries of the world."

Clinical • Late-breaking abstract • Anemia • Hematological Disorders • Infectious Disease • Malaria

Genetic diversity and molecular markers of Plasmodium falciparum drug resistance in two different malaria-endemic areas from 2016-2022 in Mali. (ASTMH 2025) - "Mutations associated with pyrimethamine resistance were highly prevalent in both sites (dhfr-108N:90% vs 91, p = 0.8), and (dhfr-59R: 88% and 88, p = 0.5)...Regarding chloroquine and amodiaquine, pfmdr1-86Y was infrequent and similar across sites (5.1% vs 4.3%; p > 0.9), while the pfmdr1-184F allele showed moderate frequencies (59% vs 54%; p = 0.5)...Genome-wide FST values were generally low (0.15) indicated region-specific genetic divergence. Despite ecological contrasts, parasite populations shared similar resistance profiles and genetic backgrounds, with localized divergence underscoring the value of ongoing genomic surveillance."

Biomarker • Late-breaking abstract • Infectious Disease • Malaria • ABCB1 • DHFR

182 - Oral Ivermectin Mass Drug Administration for Malaria Elimination: Results from Five Cluster Randomized Trials in Sub-Saharan Africa (ASTMH 2025) - "Since then, Phase 3 trials evaluating MDA with ivermectin and dihydroartemisinin-piperaquine in The Gambia (MASSIV) and Guinea-Bissau (MATAMAL), ivermectin MDA with Seasonal Malaria Chemoprophylaxis (SMC) (monthly administration of sulfadoxine-pyrimethamine plus amodiaquine during the malaria transmission season to children under 5 years old) in Burkina Faso (RIMDAMAL II), and ivermectin MDA in humans and livestock in two trials in Kenya and Mozambique (BOHEMIA) have been completed. The final results from each of these trials will be presented and discussed in context. #InfectiousDisease #ClinicalResearch #FieldStudies #TranslationalScience #NTDs #Elimination"

Clinical • Infectious Disease • Malaria • Novel Coronavirus Disease

Anopheles mosquitoes exposed to long-acting antimalarials via drug-spiked bloodmeal absorb drug but do not suffer fitness cost (ASTMH 2025) - "We did not observe any significant differences in feeding rates, flying behavior, fertility (eggs laid and percent laying), or viability (up to 14d) after ingestion of amodiaquine (or its metabolite desethylamodiaquine (DEAQ)), piperaquine, and sulfadoxine-pyrimethamine in lab An. Our results show biochemical evidence of antimalarial absorption into Anopheles hemolymph following bloodmeal ingestion. Future work will assess antimalarial impact on infected mosquitoes, which could in turn influence drug resistance spread."

Infectious Disease

Understanding and maximizing the community impact of seasonal malaria chemoprevention: a randomized controlled trial in a high malaria burden setting (ASTMH 2025) - "Seasonal Malaria Chemoprevention (SMC) currently involves administration of Sulfadoxine-Pyrimethamine plus Amodiaquine to children below 5 years (<5y) during the peak season. A total of 447 incident malaria cases were detected during the study period, with a lower incidence in children <5y in arm 2 versus arm 1 (Incidence Rate Ratio 0.42 (0.27 -0.69), p<0.001) and in children 5-9y between arms 3 and 2 (IRR 0.31 (0.20, 0.49), p<0.001. In this comprehensive evaluation of SMC in a high malaria burden setting, we observed lower plasma drug levels and higher malaria incidence when SMC was implemented programmatically as compared to research-quality DOT and a marked reduction in malaria if SMC was extended to older children."

Clinical • Infectious Disease • Malaria

Key lessons from integrating SMC and a community-based catch-up strategy for pregnant women and children under five for ANC and immunization (ASTMH 2025) - "As part of the SMC campaign, Community health workers (CHWs) administered sulfadoxine-pyrimethamine and amodiaquine (SPAQ) door-to-door and identifyed 23,817 children who had missed vaccinations, including 2,389 zero dose children, and 4,651 pregnant women who had missed or not attended prenatal consultations. However, challenges remain, particularly regarding CHW workload and logistical resources. Strengthened planning and support for CHWs are essential to ensure the sustainability and effectiveness of this integrated approach."

Clinical • Infectious Disease • Malaria

Enhancing Cohort Retention through supervision: Lessons from the 2024 Seasonal Malaria Chemoprevention Implementation in Katsina and Taraba States, Nigeria (ASTMH 2025) - "Seasonal Malaria Chemoprevention (SMC) aims to prevent malaria in children under five in regions with high seasonal transmission through monthly administration of Sulphadoxine-Pyrimethamine plus Amodiaquine (SPAQ) over four to five cycles, usually June to October. Administrative supervision remained above 99% per cycle. The intervention shows that data-driven strategies, real-time monitoring, and regular feedback can significantly improve SMC outcomes and cohort retention."

Human Immunodeficiency Virus • Infectious Disease • Malaria

Logistics Preparedness: Ensuring Timely Commodity Availability for Large-Scale ITN and SMC Integrated Malaria Campaigns (ASTMH 2025) - "Strategic logistics planning and execution were implemented to support the large-scale delivery of ITNs and Sulfadoxine Pyrimethamine and Amodiaquine (SPAQ) for SMC to each of the states ahead of the integrated campaigns. These strategies ensured commodity availability in integrated malaria campaigns that could be replicated in future integrated health interventions. Strengthening logistics preparedness for integrated malaria campaigns in Nigeria remains a cornerstone of achieving universal health coverage while ensuring commodity availability for malaria elimination."

Infectious Disease • Malaria

Risk assessment for clinical malaria occurrence among Seasonal malaria chemoprevention (SMC) eligible children with respect to their nutritional status: A prospective cohort study in Sirakorola, Mali (ASTMH 2025) - "Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine effectively reduces malaria-related morbidity and mortality among eligible children in areas with intense seasonal transmission. With similar coverage and related drugs effects for SMC, undernourished children treated form SMC are more affected with clinical malaria and present with high parasite load. An integrated program with SMC delivery and malnutrition case detection and management could be an alternative for the areas where SMC is implemented for better outcomes."

Clinical • Anemia • Hematological Disorders • Infectious Disease • Malaria

Seasonal Malaria Chemoprevention (SMC) as an Opportunity to Boost Malaria Vaccination Coverage in the Integrated Health Service (IHS) Project Area in Burkina Faso (ASTMH 2025) - "The same community distributors (CDs) were responsible for administering the Sulfadoxine-Pyrimethamine + Amodiaquine (SP+AQ) and tracking down children who had missed RTS, S doses, at no extra cost...Integrating RTS,S vaccination into SMC activities may improve the coverage rate in RTS,S. The main difficulty is the lack of a formal tracking mechanism for children who had missed the RTS,S doses and were referred and vaccinated."

Infectious Disease • Malaria